{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:11:12Z","timestamp":1784247072658,"version":"3.55.0"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR180061"],"award-info":[{"award-number":["RR180061"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>B\u2010Raf V600E mutations account for about half of all skin cutaneous melanoma cases, and patients with this mutation are sensitive to BRAF inhibitors. However, aberrations in other genes in the MAPK\/ERK pathway may cascade a similar effect as B\u2010Raf V600E mutations, rendering those patients sensitive to BRAF inhibitors. We rationalized that defining a signature based on B\u2010Raf pathway activity may be more informative for prognosis and drug sensitivity prediction than a binary indicator such as mutation status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, we defined a B\u2010Raf signature score using RNA\u2010seq data from TCGA. A higher score is shown to not only predict B\u2010Raf mutation status, but also predict other aberrations that could similarly activate the MAPK\/ERK pathway, such as B\u2010Raf amplification, RAS mutation, and EGFR amplification.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We showed that patients dichotomized by the median B\u2010Raf score is more significantly stratified than by other metrics of measuring B\u2010Raf aberration, such as mutation status, gene expression, and protein expression. We also demonstrated that high B\u2010Raf score predicts higher sensitivity to B\u2010Raf inhibitors SB590885 and PLX4720, as expected, but also correlated with sensitivity to drugs targeting other relevant oncogenic pathways.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The BRAF signature may better help guide targeted therapy for melanoma, and such a framework can be applied to other cancers and mutations to provide more information than mutation status alone.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4491","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T10:14:04Z","timestamp":1642587244000},"page":"1232-1243","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A B\u2010Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies"],"prefix":"10.1002","volume":"11","author":[{"given":"Kevin","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Electrical and Computer Engineering Texas A&amp;M University  College Station Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biosciences Rice University  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5002-3417","authenticated-orcid":false,"given":"Chao","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medicine Baylor College of Medicine  Houston Texas USA"},{"name":"Dan L Duncan Comprehensive Cancer Center Baylor College of Medicine  Houston Texas USA"},{"name":"Institute for Clinical and Transcriptional Research Baylor College of Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008404"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2217\/mmt.15.38"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.104"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479\u20105876\u201010\u201085"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.12703\/P5\u201011"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010018\u20100884\u20108"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.185"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.415"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201008\u20100431"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20100759"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.01.021"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2008.01.002"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2668"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2020.02.132"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.283"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253\u2010020\u201000837\u20109"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201013\u20100424"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388\u2010019\u20101074\u20101"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102105\u20108\u2010452"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174153"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742\u20104658.2005.04763.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209379"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111342"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature23291"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0092\u20108674(04)00215\u20106"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.15.426808"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201016\u20101541"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/82_2011_163"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050052"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.3171\/2016.2.JNS1633"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201006\u20102554"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711741105"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20103214"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018\u2010016\u20102297\u20108"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj941"},{"issue":"11","key":"e_1_2_10_41_1","first-page":"3747","article-title":"Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiDTM lenalidomide","volume":"31","author":"Fryer RA","year":"2011","journal-title":"Anticancer Res"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2013.4.6.8"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208160"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943\u2010020\u20101144\u20106"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4491","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4491","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4491","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T06:24:05Z","timestamp":1693117445000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/cam4.4491"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4491","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"2021-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}